Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis

Table 1

Comparison of outcome variables before treatment with adalimumab and at the final visit.

Variable	Week 0 (baseline)	Month 6 (final visit)	𝑃 value
Anterior chamber inflammation	2.02 (1.16)	0.42 (0.62)	<0.001
Posterior chamber inflammation	2.38 (2.97)	0.35 (0.71)	<0.005
Macular thickness, 𝜇	304.54 (125.03)	230.87 (31.12)	<0.001
Immunosuppression load	8.10 (3.99)	5.08 (3.76)	<0.001

Data as mean (standard deviation).